Compare CWD & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWD | NOTV |
|---|---|---|
| Founded | 2009 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.8M |
| IPO Year | 2022 | 1997 |
| Metric | CWD | NOTV |
|---|---|---|
| Price | $0.97 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 249.2K | ★ 657.4K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | $20,097,000.00 | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | $19.17 | $5.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $0.87 | $0.22 |
| 52 Week High | $46.21 | $3.31 |
| Indicator | CWD | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 45.71 |
| Support Level | $0.91 | $0.24 |
| Resistance Level | $1.13 | $0.34 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 32.22 | 32.96 |
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.